BioNTech SE
LSE:0A3M
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BioNTech SE
LSE:0A3M
|
DE |
|
S
|
S&P Global Inc
XBER:MHL
|
US |
|
I
|
Impala Platinum Holdings Ltd
SWB:IPHB
|
ZA |
|
G
|
General Electric Co
BMV:GE
|
US |
|
B
|
BCE Inc
NYSE:BCE
|
CA |
|
R
|
Rajthanee Hospital PCL
SET:RJH
|
TH |
|
Toyota Motor Corp
NYSE:TM
|
JP |
|
Globant SA
NYSE:GLOB
|
LU |
|
S
|
Skechers USA Inc
XBER:SKAA
|
US |
|
APA Corp (US)
LSE:0HGC
|
US |
|
China Mobile Ltd
SSE:600941
|
CN |
|
T
|
Trane Technologies PLC
XBER:2IS
|
IE |
|
L
|
Lenovo Group Ltd
XBER:LHL
|
CN |
|
K
|
Kingspan Group PLC
SWB:KRX
|
IE |
|
CGI Inc
F:CJ5A
|
CA |
|
W
|
Wolters Kluwer NV
XHAM:WOSB
|
NL |
|
A
|
ASML Holding NV
XBER:ASME
|
NL |
|
C
|
Christian Dior SE
OTC:CHDRY
|
FR |
|
Cathay Media and Education Group Inc
HKEX:1981
|
CN |
|
L
|
Lundin Mining Corp
F:GXD
|
CA |
|
Naturgy Energy Group SA
LSE:0NPV
|
ES |
|
I
|
Intercontinental Exchange Inc
LSE:0JC3
|
US |
Bankruptcy Probability
BioNTech SE's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
BioNTech SE Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DE |
|
BioNTech SE
NASDAQ:BNTX
|
23.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
181.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
OpGen Inc
NASDAQ:OPGN
|
156.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
76.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
BioNTech SE's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, BioNTech SE has total debt of 246.1m EUR. This includes both short-term (0 EUR) and long-term (246.1m EUR) debt.
You can find a full breakdown on its Balance Sheet.
